Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein−Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma

Gastroenterology

Volumn 152, Issue 6, 2017, Pages 1395-1406.e10

  Nakagawa, Hidetoshi ^a,b   Mizukoshi, Eishiro ^a   Kobayashi, Eiji ^b   Tamai, Toshikatsu ^a,b   Hamana, Hiroshi ^b   Ozawa, Tatsuhiko ^b   Kishi, Hiroyuki ^b   Kitahara, Masaaki ^a   Yamashita, Tatsuya ^a   Arai, Kuniaki ^a   Terashima, Takeshi ^a   Iida, Noriho ^a   Fushimi, Kazumi ^a   Muraguchi, Atsushi ^b   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cancer; Cytotoxic T Lymphocyte; Epitope; Immunotherapy

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN 357; ALPHA FETOPROTEIN 403; CANCER VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; MONTANIDE ISA 51; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PRURITUS; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RUBOR; SKIN DISEASE; SKIN INDURATION; SKIN PRURITUS; SKIN REDNESS; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CHEMISTRY; CLINICAL TRIAL; COCULTURE; DIAGNOSTIC IMAGING; HEP-G2 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; MIDDLE AGED; SECRETION (PROCESS); VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; COCULTURE TECHNIQUES; FEMALE; HEP G2 CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LIVER NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 85018818275     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.02.001     Document Type: Article

References (37)

1. 1 Parkin, D.M., Global cancer statistics in the year 2000. Lancet Oncol 2 (2001), 533–543.
2. 2 El-Serag, H.B., Rudolph, K.L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007), 2557–2576.
3. 3 Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
4. 4 Siegel, A.B., Olsen, S.K., Magun, A., et al. Sorafenib: where do we go from here?. Hepatology 52 (2010), 360–369.
5. 5 Pinter, M., Hucke, F., Graziadei, I., et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263 (2012), 590–599.
6. 6 Tomasi, T.B. Jr., Structure and function of alpha-fetoprotein. Annu Rev Med 28 (1977), 453–465.
7. 7 Butterfield, L.H., Meng, W.S., Koh, A., et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166 (2001), 5300–5308.
8. 8 Meng, W.S., Butterfield, L.H., Ribas, A., et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61 (2001), 8782–8786.
9. 9 Butterfield, L.H., Ribas, A., Dissette, V.B., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12 (2006), 2817–2825.
10. 10 Thimme, R., Neagu, M., Boettler, T., et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 48 (2008), 1821–1833.
11. 11 Mizukoshi, E., Nakamoto, Y., Tsuji, H., et al. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 118 (2006), 1194–1204.
12. 12 Mizukoshi, E., Nakamoto, Y., Arai, K., et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 53 (2011), 1206–1216.
13. 13 Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
14. 14 Kobayashi, E., Mizukoshi, E., Kishi, H., et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med 19 (2013), 1542–1546.
15. 15 Chung, S., Strominger, J.L., Regulation of T-cell antigen receptor (TCR) alpha-chain expression by TCR beta-chain transcripts. Proc Natl Acad Sci U S A 92 (1995), 3712–3716.
16. 16 Tajima, K., Ito, Y., Demachi, A., et al. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. International journal of cancer. J Intl Cancer 110 (2004), 403–412.
17. 17 Seifert, U., Bialy, L.P., Ebstein, F., et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142 (2010), 613–624.
18. 18 Greten, T.F., Forner, A., Korangy, F., et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer, 10, 2010, 209.
19. 19 Sawada, Y., Yoshikawa, T., Nobuoka, D., et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 18 (2012), 3686–3696.
20. 20 Mizukoshi, E., Nakamoto, Y., Arai, K., et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer 126 (2010), 2164–2174.
21. 21 Nakamoto, Y., Mizukoshi, E., Kitahara, M., et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 163 (2011), 165–177.
22. 22 Mizukoshi, E., Yamashita, T., Arai, K., et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57 (2013), 1448–1457.
23. 23 Dziubianau, M., Hecht, J., Kuchenbecker, L., et al. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant 13 (2013), 2842–2854.
24. 24 Cukalac, T., Moffat, J.M., Venturi, V., et al. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus. Vaccine 27 (2009), 6755–6761.
25. 25 Flecken, T., Schmidt, N., Hild, S., et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59 (2014), 1415–1426.
26. 26 Mine, T., Sato, Y., Noguchi, M., et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10 (2004), 929–937.
27. 27 Johnson, L.A., Heemskerk, B., Powell, D.J. Jr., et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177 (2006), 6548–6559.
28. 28 Johnson, L.A., Morgan, R.A., Dudley, M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114 (2009), 535–546.
29. 29 Gros, A., Parkhurst, M.R., Tran, E., et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22 (2016), 433–438.
30. 30 Sherwood, A.M., Emerson, R.O., Scherer, D., et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother 62 (2013), 1453–1461.
31. 31 Chen, Z., Zhang, C., Pan, Y., et al. T cell receptor beta-chain repertoire analysis reveals intratumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma. J Pathol 239 (2016), 450–458.
32. 1 Mizukoshi, E., Nakamoto, Y., Marukawa, Y., et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006), 1284–1294.
33. 2 Ikeda-Moore, Y., Tomiyama, H., Miwa, K., et al. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol 159 (1997), 6242–6252.
34. 3 Kuzushima, K., Hayashi, N., Kimura, H., et al. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98 (2001), 1872–1881.
35. 4 Mizukoshi, E., Nakamoto, Y., Tsuji, H., et al. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 118 (2006), 1194–1204.
36. 5 Kobayashi, E., Mizukoshi, E., Kishi, H., et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med 19 (2013), 1542–1546.
37. 6 Leisegang, M., Engels, B., Meyerhuber, P., et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med 86 (2008), 573–583.